This article, published in The New England Journal of Medicine, discusses the methods and results of two studies conducted in Africa to evaluate a new meningococcal A conjugate vaccine. The conclusion of the studies is that the new vaccine has a safety profile similar to that of a licensed polysaccharide vaccine but elicits a significantly stronger and more persistent response from functional antibodies against group A meningococcus, when tested in Africans between 1 and 29 years of age.

Author(s): Sow SO, Okoko BJ, Diallo A, et al.

Published: 2011

Resource types: Peer-reviewed journal

Diseases: Meningococcus

Topics: Disease/vaccine specific information

Regions: Africa